Profile_bird

Hey there! GENbio is using Twitter.

Twitter is a free service that lets you keep in touch with people through the exchange of quick, frequent answers to one simple question: What are you doing? Join today to start receiving GENbio's tweets.

Already using Twitter
from your phone? Click here.

GENbio

  1. Calbiotech Wins Phase I SBIR Contract to Develop Blood-Based Dengue Fever Diagnostic http://bit.ly/1d9R2w
  2. FDA Sanctions Gloucester Pharmaceuticals’ Cutaneous T-Cell Lymphoma Therapy http://bit.ly/1rg25O
  3. Researchers Design Molecules that Trigger Immune Response to HIV and Prostate Cancer http://bit.ly/beovF
  4. Applying Real-Time PCR to Strain Identification http://bit.ly/2jI25
  5. Third Option for Stem Cell Research Emerges http://bit.ly/3yA038
  6. Nanotechnologists Create Artificial Pore http://bit.ly/qP0sd
  7. Third Option for Stem Cell Research Emerges http://bit.ly/3yA038
  8. New Capabilities Fortify Biodefense Tools http://bit.ly/3VvtFu
  9. Opening Up the Lines of Communication at the Patent Office http://bit.ly/2y3c1f
  10. Product & Service Deals for 11/5: QED and Genovis; Sanofi-Aventis & Aureus; Broad Institute and Illumina http://bit.ly/3TFF5P
  11. Genmab to Sell Manufacturing Facility and Cut 300 Jobs http://bit.ly/3CjZLM
  12. Pfizer Pays $3.1M to Re-Up Agreement with Ligand for an Additional Year http://bit.ly/1xY8xv
  13. NIAID Commissions GenVec for HIV and Influenza Vaccine Development for $2.6M http://bit.ly/rlfFG
  14. Micromet Axes Alliance with MedImmune Regaining Rights to Clinical-Stage Cancer Drug http://bit.ly/1oq9dO
  15. Biovitrum to Buy Swedish Orphan for Over $500M http://bit.ly/3hH6rA
  16. Germany Sanctions Novartis’ Cell Culture-Based H1N1 Flu Vaccine http://bit.ly/2kJLMl
  17. BIO-Europe 2009 Day 3 http://bit.ly/4nATi1
  18. Our next webinar will be on 11/18 and is called Overcoming LC/MS Data Overload in Biotherapeutic Peptide Mapping http://bit.ly/39mSYr
  19. Animal Imaging Transforms Development http://bit.ly/1bAhuK
  20. Shaken Bioreactors Provide Culture Alternative http://bit.ly/1FEPi2